Climb Bio, Inc. (CLYM)
| Market Cap | 836.27M +418.5% |
| Revenue (ttm) | n/a |
| Net Income | -57.62M |
| EPS | -0.83 |
| Shares Out | 57.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,094,427 |
| Open | 14.49 |
| Previous Close | 14.25 |
| Day's Range | 14.30 - 14.96 |
| 52-Week Range | 1.54 - 18.33 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 27.57 (+89.35%) |
| Earnings Date | Aug 6, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $27.57, which is an increase of 89.35% from the latest price.
News
Climb Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials and data readouts are planned through 2025, supported by a strong financial position.
Climb Bio price target raised to $25 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on Climb Bio (CLYM) to $25 from $18 and keeps an Outperform rating on the shares. The recent CLYM116 reveal illustrates a best-in-class clinical…
Climb Bio price target raised to $30 from $24 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Climb Bio (CLYM) to $30 from $24 and keeps a Buy rating on the shares. The CLYM116 initial Phase 1 data “display…
Climb Bio management to meet with Piper Sandler
Meeting to be held on September 11 hosted by Piper Sandler.
Climb Bio price target raised to $30 from $26 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Climb Bio (CLYM) to $30 from $26 and keeps a Buy rating on the shares after the company shared…
Jade Biosciences price target raised to $48 from $25 at Clear Street
Clear Street raised the firm’s price target on Jade Biosciences (JBIO) to $48 from $25 and keeps a Buy rating on the shares. The firm believes Climb Bio’s (CLYM) CLYM116…
Climb Bio price target raised to $32 from $20 at BTIG
BTIG raised the firm’s price target on Climb Bio (CLYM) to $32 from $20 and keeps a Buy rating on the shares. The firm notes CLYM116’s Phase 1 results were…
Climb Bio price target raised to $25 from $21 at Baird
Baird raised the firm’s price target on Climb Bio (CLYM) to $25 from $21 and keeps an Outperform rating on the shares after the company shared Phase 1 healthy volunteer…
Climb Bio price target raised to $40 from $23 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Climb Bio (CLYM) to $40 from $23 and keeps an Overweight rating on the shares after the company announced…
Climb Bio Transcript: Study result
CLYM116, a next-generation anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression, robust reductions in IgA and related biomarkers, and a favorable safety profile in phase I. Modeling supports a 12-week dosing regimen, with phase II underway and phase III planned for 2027.
Climb Bio Press release: Study result
Climb Bio issued a press release on September 3, 2026, disclosing material business information to investors.
Climb Bio Slides: Study result
Climb Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Climb Bio announces initial data from CLYM116 trial
Climb Bio (CLYM) announced initial data from the ongoing Phase 1 trial evaluating CLYM116, an anti-APRIL monoclonal antibody, and provided updates on its strategy for further development in IgA nephro...
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse even...
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to...
Climb Bio price target raised to $24 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Climb Bio (CLYM) to $24 from $20 and keeps a Buy rating on the shares. The firm views the company’s competitive positioning…
Climb Bio price target raised to $25 from $17 at Truist
Truist raised the firm’s price target on Climb Bio (CLYM) to $25 from $17 and keeps a Buy rating on the shares.
Climb Bio reports Q2 EPS (18c), consensus (21c)
“2026 is proving to be a defining year for Climb Bio (CLYM), and I am thrilled by the team’s execution,” said Aoife Brennan, President and Chief Executive Officer of Climb…
Climb Bio Earnings release: Q2 2026
Climb Bio released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Climb Bio Quarterly report: Q2 2026
Climb Bio has published its Q2 2026 quarterly earnings report on August 6, 2026.
Climb Bio Slides: Investor presentation
Climb Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Climb Bio initiated with an Outperform at RBC Capital
RBC Capital analyst Nevin Varghese initiated coverage of Climb Bio (CLYM) with an Outperform rating and $23 price target Climb Bio offers an attractive second half of 2026 catalyst profile,…
Climb Bio price target raised to $20 from $19 at BTIG
BTIG analyst Julian Harrison raised the firm’s price target on Climb Bio (CLYM) to $20 from $19 and keeps a Buy rating on the shares. Budoprutug, an anti-CD19 monoclonal antibody,…
Climb Bio announces initial data from budoprutug study at EHA
Climb Bio (CLYM) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopen...
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment o...